Early to Phase II drugs currently under investigation for the treatment of liver fibrosis (Q38303313)

1 September 2017

1 reference

title

Early to Phase II drugs currently under investigation for the treatment of liver fibrosis (English)

1 reference

1 September 2017

Peter Hauff

1

1 reference

1 September 2017

Ulrich Gottwald

series ordinal

2

1 reference

1 September 2017

Matthias Ocker

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

30 December 2014

1 reference

Expert Opinion on Investigational Drugs

1 September 2017

1 reference

1 September 2017

24

1 reference

1 September 2017

309-327

1 reference

1 September 2017

3

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

1 September 2017

1 reference

Pathogenesis of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The global impact of hepatic fibrosis and end-stage liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Diagnosis of liver cirrhosis in England, a cohort study, 1998-2009: a comparison with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Underestimation of liver-related mortality in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The burden of liver disease in Europe: a review of available epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Beverage-specific alcohol consumption and cirrhosis mortality in a group of English-speaking beer-drinking countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Recent advances in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

NAFLD in Asia--as common and important as in the West

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Evolving challenges in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Mechanisms of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

21 January 2018

Liver fibrogenic cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The portal fibroblast: not just a poor man's stellate cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hematopoietic origin of hepatic stellate cells in the adult liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The bone marrow functionally contributes to liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Matrix as a modulator of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatic inflammation and fibrosis: functional links and key pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Transforming growth factor beta and the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Interleukin-1 participates in the progression from liver injury to fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Tumor necrosis factor-α promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

CCL5: a double-edged sword in host defense against the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Toll-like receptor 3 and 7/8 function is impaired in hepatitis C rapid fibrosis progression post-liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Human lysyl oxidase-like 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

MiR-29b inhibits collagen maturation in hepatic stellate cells through down-regulating the expression of HSP47 and lysyl oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Macrophage heterogeneity in liver injury and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Alcohol induced hepatic fibrosis: role of acetaldehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Fibrogenesis in alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Interactions between the intestinal microbiome and liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Fructose as a key player in the development of fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Modulation of autophagy for the treatment of liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Autophagy in human health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Regulation of mammalian autophagy in physiology and pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Functions of autophagy in normal and diseased liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatitis C virus core protein activates autophagy through EIF2AK3 and ATF6 UPR pathway-mediated MAP1LC3B and ATG12 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatitis B virus x protein induces autophagy via activating death-associated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Autophagy required for hepatitis B virus replication in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Autophagy regulates lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Autophagy in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Chloroquine improved carbon tetrachloride-induced liver fibrosis through its inhibition of the activation of hepatic stellate cells: role of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Clinical evidence for the regression of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Anti-fibrotic therapy: lost in translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Therapy for fibrotic diseases: nearing the starting line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Anti-fibrogenic strategies and the regression of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A first step towards a mouse model for hepatitis C virus infection containing a human immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Therapy of experimental NASH and fibrosis with galectin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Development of a new animal model of liver cirrhosis in swine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Liver lobe volumes and the ratios of liver lobe volumes to spleen volume on magnetic resonance imaging for staging liver fibrosis in a minipig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Spleen size measured on enhanced MRI for quantitatively staging liver fibrosis in minipigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Magnetic resonance-based total liver volume and magnetic resonance-diffusion weighted imaging for staging liver fibrosis in mini-pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Effects of bile acids on biliary epithelial cell proliferation and portal fibroblast activation using rat liver slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Fibrogenic cell phenotype modifications during remodelling of normal and pathological human liver in cultured slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Assessment of fibrosis in chronic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Noninvasive evaluation of NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Molecular MRI of collagen to diagnose and stage liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Non-invasive assessment of liver fibrosis: it is time for laboratory medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Liver collagen in cirrhosis correlates with portal hypertension and liver dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Evolving therapies for liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Endpoints and clinical trial design for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Serelaxin : a potential new drug for the treatment of acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The traditional ayurvedic medicine, Eugenia jambolana (Jamun fruit), decreases liver inflammation, injury and fibrosis during cholestasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Anti-fibrotic effects of the anthocyanins isolated from the purple-fleshed sweet potato on hepatic fibrosis induced by dimethylnitrosamine administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Effect of cyanidin 3-O-beta-glucopyranoside on hepatic stellate cell proliferation and collagen synthesis induced by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Comparison of purple carrot juice and β-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Pirfenidone for the treatment of idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

The treatment of idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

NAD(P)H:quinone oxidoreductase 1 activation reduces blood pressure through regulation of endothelial nitric oxide synthase acetylation in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Antifibrotic activity of anthocyanidin delphinidin in carbon tetrachloride-induced hepatotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Role of diet and nutritional management in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A nontumorigenic variant of FGF19 treats cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Safely targeting cancer stem cells via selective catenin coactivator antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Vitamin D in liver diseases: from mechanisms to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.997874

10.1517/13543784.2015.997874

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference